Ubs Oconnor LLC Arcutis Biotherapeutics, Inc. Transaction History
Ubs Oconnor LLC
- $1.46 Billion
- Q3 2024
A detailed history of Ubs Oconnor LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 92,019 shares of ARQT stock, worth $913,748. This represents 0.06% of its overall portfolio holdings.
Number of Shares
92,019Holding current value
$913,748% of portfolio
0.06%Shares
3 transactions
Others Institutions Holding ARQT
# of Institutions
196Shares Held
129MCall Options Held
746KPut Options Held
82K-
Jennison Associates LLC11.7MShares$116 Million0.07% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$109 Million2.84% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.7MShares$106 Million3.92% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$87.2 Million4.4% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$85.6 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $598M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...